TMC - Technology, Media & Communications

Hamburg – MDAX-listed CTS Eventim AG & Co. KGaA, the number one provider of ticketing services in Europe and number two in the world, has today entered into a put option agreement with companies in the listed French media group Vivendi. This grants Vivendi the right to sell to CTS Eventim all the shares in the companies that are part of its festival and international ticketing activities. Vivendi will now conduct a consultation procedure with the relevant employee representative bodies so that it can decide on accepting the put option. Vivendi’s ticketing business includes See Tickets UK, the second-biggest ticketing firm in England, along with other companies in Europe and the US. These companies sold a total of around 44 million tickets in the 2023 financial year. The deal does not include the shares in Vivendi’s French ticketing company, See Tickets SAS. The festival business operated by Vivendi includes companies from England and France that organise festivals such as Junction 2 and Garorock. CMS advised CTS Eventim on all aspects of the transaction. The team headed by Henrik Drinkuth worked closely with several CMS offices in countries including France, England, Spain, Switzerland and the Netherlands. CMS Germany Dr Henrik Drinkuth, Lead Partner Dr Hendrik Quast, Senior Associate, both Corporate/M&A Prof. Malte Grützmacher, Partner, IT/Data Pro­tec­tion Chris­toff Soltau, Part­ner Al­ex­an­der Laute, Senior Associate, both Competition Dr Martin Gerecke, Partner, Media Law CMS France Alexandra Rohmert Vincent Desbenoit Dylan Allali, all Corporate/M&A Claire Van­nini  Guil­laume Melot, both Competition CMS UK John Enser, TMT Nick Crosbie  Jade Tran  Maria Doran, all Corporate/M&A CMS Spain Luis Miguel De Dios Jorge Peris Hevia, both Corporate/M&A and Commercial CMS Portugal Miguel Santos Ferreira, Corporate/M&A and Commercial CMS Switzerland Stefan Brunnsch­weiler An­drea Relly Anna Mast, all Corporate/M&A CMS Netherlands Elmer Veenman Bob Barnhoorn, both Corporate/M&A and CommercialPress Con­tact presse@cms-hs. com

Ham­burg/Stut­tgart – Main Street Capital Corporation, a publicly traded financial investor based in Houston, Texas, has acquired Maass Global Group through one of its portfolio companies, Gulf Manufacturing, LLC. The Essen-based company is a global leader in the manufacture and sale of flanges and forged specialty products, forged steel bars, seamless tubes and fittings made of duplex, stainless steel and high-nickel alloys. In addition to its headquarters in Essen, the Maas Global Group has further locations in the Netherlands, the United Kingdom, India, Singapore and the United Arab Emirates.A CMS team led by Dr. Eckart Gottschalk and Dr. Kai Wallisch provided comprehensive legal advice to Main Street Capital Corporation on this transaction. In addition to corporate law advice, the focus was on the legal implementation of the financing. As part of the transaction, CMS Germany worked closely with CMS law firms from the Netherlands, Singapore and the United Arab Emirates as well as the American law firm Locke Lord and AZB & Partners from India. Main Street Capital Corporation is a publicly traded investment company with a market capitalization of approximately USD 3.9 billion. It specializes in long-term financing of middle-market companies in various industries through management buyouts, re­cap­it­al­iz­a­tions, growth financing and acquisitions. With the investment to acquire Maas Global Group, Main Street Capital Corporation is deepening its existing investment in the manufacturing of flanges, fittings and other specialty products for industrial applications. CMS Germany Dr. Eckart Gottschalk, Lead Partner Dr. Kai Wallisch, Lead Partner Dr. Paul Kintrup, Senior As­so­ci­ate Mil­itsa Decheva Petrova, Senior Associate Dr. Alexander Weinhold, Senior As­so­ci­ate Tjorben Drawe, Associate Sonja Schanze, As­so­ci­ate Kath­rin Dengel, Associate, all Corporate/M&A Dr. Marc Seibold, Partner Anne Waßmuth, Counsel Carla Kaeber, Associate, all Banking & Finance Dr. Hans Fabian Kiderlen, Principal Counsel Theresa Friedle, Associate, both Real Estate & Public Dr. Michael Kraus, Partner Thomas Fröhlich, Counsel, both TMC Dr. Jacob Hinze, Counsel, Employment Law Dr. Martin Mohr, Partner, Tax Christoff Henrik Soltau, Partner Dr. Robert Bodewig, Senior Associate, both Antitrust, Competition & Trade Kai Neuhaus, Partner Moritz Pottek, Counsel, both Brussel EU Law Office CMS Netherlands Roman Tarlavski, Partner Maarten Feenstra, Associate Fleur Assendelft de Coningh, Associate Anne Fleur Krijthe, Candidate civil law notary CMS Singapore Toby Grainger, Partner Leslie Tay, Associate CMS UAE Patrik Daintry, Partner Fawzi Oueidat, Associate Locke Lord Greg Heath, Partner Nicholas Jennings, Partner Jason Ulezalka, Partner Case Towslee, Associate Jake Chagoury, Associate Mason Marek, Associate AZB & Partners Srinath Dasari, Senior Partner Gautam Rego, Partner Yash Anand, Associate Gopika Menon, AssociatePress Con­tact presse@cms-hs. com

Munich – CMS advises the sellers of Cardior Pharmaceuticals in the potential acquisition of the company by Novo Nordisk. Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. The agreement includes Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure. The closing of the acquisition is subject to receipt of applicable regulatory approvals and other customary conditions. It is expected to happen in the second quarter of 2024.A CMS team headed by Lead Partners Stefan-Ulrich Müller, Dr Tilman Weichert and Jörg Schrade advised the sellers of Cardior Pharmaceuticals on all legal aspects of the transaction. Cardior Pharmaceuticals GmbH, based in Hannover, Germany, is a leading clinical-stage bio­phar­ma­ceut­ic­al company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. CMS Germany Stefan-Ulrich Müller, Lead Partner Dr Tilman Weichert, Lead Partner Dr Michael Wangemann, Partner Dr Kai Wallisch, Partner Dr Thomas Mühl, Principal Coun­sel Se­basti­an Hummel, Senior As­so­ci­ate Vikt­or­ia Barthel, Senior As­so­ci­ate Mar­i­elouise Emmer, Senior Associate Dr Carl-Friedrich Thoma, Senior Associate Dr Stefan Kühl, Senior Associate Dr Alexander Weinhold, Senior Associate Maria Kucher, Associate Jonas Ohmann, Associate Dr Josephine Doll, Associate Dr Christian Seeburger, Associate Sonja Schanze, Associate, all Corporate/M&A Dr Marie-Luisa Loheide, Associate, Private Clients Jörg Schrade, Lead Partner Eduard Kosavtsev, Senior Associate, both Tax Stefan Lehr, Partner, Antitrust, Competition & Trade Stefan Lüft, Partner, IP Dr Benedikt Forschner, Partner, Labor, Employment & Pensions Dr Markus Kaulartz, Partner Dr Fiona Savary, Counsel Dr Felix Glocker, Senior Associate, all TMC Dr Tilman Niedermaier, Partner Susanne Schwalb, Partner, both Dispute ResolutionPress Con­tact presse@cms-hs. com

Hamburg – Hanseatic Energy Hub GmbH (HEH) has achieved financial close for the project financing to develop and realise the planned terminal for liquefied gases in Stade. Total investment is some EUR 1.6 billion. Achieving financial close represents a major milestone for Hanseatic Energy Hub GmbH’s land-based terminal.A multi-dis­cip­lin­ary and multi-location CMS team headed by Dr Hilke Herchen and Dr Holger Kraft advised Hanseatic Energy Hub GmbH on developing the project and on preparations to secure the project financing. This included corporate law advice with a particular focus on developing and optimising corporate governance, and on the associated links to the project financing. This advice marks a continuation of the existing close cooperation between HEH and CMS. The CMS team has been providing advice on an ongoing basis since the start of the project, with support for project development around corporate, operation & maintenance and real estate matters in particular. This has included advising on various shareholders joining the project, with a recent example being Enagás S.A. as industrial partner in June 2023. The CMS team conducted a comprehensive due diligence check to put the project financing on a solid footing. The first expansion phase of the project will see an emission-free terminal begin operating in 2027. Its infrastructure is also approved for bio-LNG and synthetic natural gas (SNG). At a later stage, the project will be switched over to hydrogen-based energy carriers such as ammonia. The planned regasification capacity is 13.3 billion cubic metres per year and the send-out capacity is 21.7 gigawatt. From March 2024 until the onshore terminal becomes operational, Hanseatic Energy Hub GmbH will also accommodate one of the five FSRUs (Floating Storage and Regasification Units) chartered by the German federal government. CMS Germany Dr Hilke Herchen, Lead Partner Dr Holger Kraft, Lead Partner Matthias Sethmann, Principal Counsel Dr Luise Pelzer, Counsel Dr Stefan Kühl, Senior Associate Dr Carl-Friedrich Thoma, Senior Associate Dr Josephine Doll, As­so­ci­ate Domin­ic Zimmer, Associate Dr Christian Seeburger, Associate, all Corporate/M&A Dr Fritz von Hammerstein, Partner Katja Meisel, Senior Associate Jan Gröschel, Senior Associate, all Per­mit­ting Mar­tin Krause, Partner Dr Sebastian Orthmann, Partner Dr Hans Fabian Kiderlen, Principal Coun­sel Chris­toph­er Schmeckel, Senior Associate Wiebke Westermann, Associate, all Real Estate Dr Friedrich von Burchard, Partner, Energy & Climate Change Dorothée Janzen, Part­ner  Chris­toph Zarth, Partner Robin Azinovic, Associate, all Commercial Dr Kerstin Block, Partner, Banking & Finance  Dr Martin Mohr, Partner Dr Olaf Thießen, Principal Counsel, both Tax Dr Sebastian Cording, Partner Dr Anna Lena Füllsack, Senior Associate, both TMC Dr Michael Bauer, Partner Luisa Thomasberger, Associate, both Antitrust, Competition & Trade Dr Philipp Nonnenmühlen, Counsel, Labor, Employment & Pensions Dr Martin Gerecke, Partner, IP Birgit Wagner, Legal Manager, Smart OperationsPress Con­tact presse@cms-hs. com

This e-learning course teaches the basics of open source compliance. The aim of the course is to raise awareness of the advantages as well as the risks and pitfalls of open source software in all these levels of the company. At the end of the course, solutions to identify risks and avoid them as best as possible through appropriate processes are shown. The e-learning course is aimed at everyone in companies who comes into contact with open source software. This includes not only management but also the IT and development department, purchasing, sales and product management.